vs

Side-by-side financial comparison of Tarsus Pharmaceuticals, Inc. (TARS) and TFS Financial CORP (TFSL). Click either name above to swap in a different company.

Tarsus Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($151.7M vs $83.7M, roughly 1.8× TFS Financial CORP). TFS Financial CORP runs the higher net margin — 26.6% vs -5.5%, a 32.1% gap on every dollar of revenue. On growth, Tarsus Pharmaceuticals, Inc. posted the faster year-over-year revenue change (128.4% vs 11.9%). TFS Financial CORP produced more free cash flow last quarter ($57.1M vs $13.0M). Over the past eight quarters, Tarsus Pharmaceuticals, Inc.'s revenue compounded faster (134.4% CAGR vs 4.2%).

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

TFS Financial Corporation is a US-based financial holding company primarily operating through its retail banking subsidiary. It offers residential mortgage loans, savings accounts, and other consumer financial products, with its core customer base concentrated in Ohio and Florida, mainly serving individual and family clients.

TARS vs TFSL — Head-to-Head

Bigger by revenue
TARS
TARS
1.8× larger
TARS
$151.7M
$83.7M
TFSL
Growing faster (revenue YoY)
TARS
TARS
+116.5% gap
TARS
128.4%
11.9%
TFSL
Higher net margin
TFSL
TFSL
32.1% more per $
TFSL
26.6%
-5.5%
TARS
More free cash flow
TFSL
TFSL
$44.1M more FCF
TFSL
$57.1M
$13.0M
TARS
Faster 2-yr revenue CAGR
TARS
TARS
Annualised
TARS
134.4%
4.2%
TFSL

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
TARS
TARS
TFSL
TFSL
Revenue
$151.7M
$83.7M
Net Profit
$-8.4M
$22.3M
Gross Margin
Operating Margin
-5.3%
34.0%
Net Margin
-5.5%
26.6%
Revenue YoY
128.4%
11.9%
Net Profit YoY
63.8%
-0.7%
EPS (diluted)
$-0.17
$0.08

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
TARS
TARS
TFSL
TFSL
Q4 25
$151.7M
$83.7M
Q3 25
$118.7M
$85.5M
Q2 25
$102.7M
$82.0M
Q1 25
$78.3M
$79.1M
Q4 24
$66.4M
$74.8M
Q3 24
$48.1M
$75.1M
Q2 24
$40.8M
$75.5M
Q1 24
$27.6M
$77.1M
Net Profit
TARS
TARS
TFSL
TFSL
Q4 25
$-8.4M
$22.3M
Q3 25
$-12.6M
$26.0M
Q2 25
$-20.3M
$21.5M
Q1 25
$-25.1M
$21.0M
Q4 24
$-23.1M
$22.4M
Q3 24
$-23.4M
$18.2M
Q2 24
$-33.3M
$20.0M
Q1 24
$-35.7M
$20.7M
Operating Margin
TARS
TARS
TFSL
TFSL
Q4 25
-5.3%
34.0%
Q3 25
-12.2%
37.9%
Q2 25
-21.6%
33.3%
Q1 25
-33.5%
33.5%
Q4 24
-36.8%
37.9%
Q3 24
-52.3%
30.7%
Q2 24
-81.6%
33.4%
Q1 24
-136.5%
33.6%
Net Margin
TARS
TARS
TFSL
TFSL
Q4 25
-5.5%
26.6%
Q3 25
-10.6%
30.4%
Q2 25
-19.8%
26.2%
Q1 25
-32.1%
26.6%
Q4 24
-34.8%
30.0%
Q3 24
-48.7%
24.2%
Q2 24
-81.6%
26.4%
Q1 24
-129.4%
26.9%
EPS (diluted)
TARS
TARS
TFSL
TFSL
Q4 25
$-0.17
$0.08
Q3 25
$-0.30
$0.09
Q2 25
$-0.48
$0.08
Q1 25
$-0.64
$0.07
Q4 24
$-0.57
$0.08
Q3 24
$-0.61
$0.07
Q2 24
$-0.88
$0.07
Q1 24
$-1.01
$0.07

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
TARS
TARS
TFSL
TFSL
Cash + ST InvestmentsLiquidity on hand
$417.3M
$456.7M
Total DebtLower is stronger
$72.4M
Stockholders' EquityBook value
$343.4M
$1.9B
Total Assets
$562.2M
$17.5B
Debt / EquityLower = less leverage
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
TARS
TARS
TFSL
TFSL
Q4 25
$417.3M
$456.7M
Q3 25
$401.8M
$429.4M
Q2 25
$381.1M
$452.6M
Q1 25
$407.9M
$463.6M
Q4 24
$291.4M
$465.9M
Q3 24
$317.0M
$463.7M
Q2 24
$323.6M
$560.4M
Q1 24
$298.5M
$594.3M
Total Debt
TARS
TARS
TFSL
TFSL
Q4 25
$72.4M
Q3 25
$72.3M
Q2 25
$72.1M
Q1 25
$72.0M
Q4 24
$71.8M
Q3 24
$71.7M
Q2 24
$71.6M
Q1 24
$29.9M
Stockholders' Equity
TARS
TARS
TFSL
TFSL
Q4 25
$343.4M
$1.9B
Q3 25
$335.1M
$1.9B
Q2 25
$332.6M
$1.9B
Q1 25
$342.5M
$1.9B
Q4 24
$224.5M
$1.9B
Q3 24
$237.5M
$1.9B
Q2 24
$252.2M
$1.9B
Q1 24
$275.2M
$1.9B
Total Assets
TARS
TARS
TFSL
TFSL
Q4 25
$562.2M
$17.5B
Q3 25
$534.6M
$17.5B
Q2 25
$495.0M
$17.4B
Q1 25
$500.8M
$17.1B
Q4 24
$377.0M
$17.1B
Q3 24
$376.3M
$17.1B
Q2 24
$376.8M
$17.0B
Q1 24
$349.3M
$17.0B
Debt / Equity
TARS
TARS
TFSL
TFSL
Q4 25
0.21×
Q3 25
0.22×
Q2 25
0.22×
Q1 25
0.21×
Q4 24
0.32×
Q3 24
0.30×
Q2 24
0.28×
Q1 24
0.11×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
TARS
TARS
TFSL
TFSL
Operating Cash FlowLast quarter
$19.3M
$58.7M
Free Cash FlowOCF − Capex
$13.0M
$57.1M
FCF MarginFCF / Revenue
8.6%
68.2%
Capex IntensityCapex / Revenue
4.2%
2.0%
Cash ConversionOCF / Net Profit
2.64×
TTM Free Cash FlowTrailing 4 quarters
$-22.3M
$167.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
TARS
TARS
TFSL
TFSL
Q4 25
$19.3M
$58.7M
Q3 25
$18.3M
$82.4M
Q2 25
$-29.4M
$26.8M
Q1 25
$-20.7M
$21.2M
Q4 24
$-22.2M
$45.5M
Q3 24
$-8.7M
$88.6M
Q2 24
$-14.4M
$96.7M
Q1 24
$-37.8M
$14.2M
Free Cash Flow
TARS
TARS
TFSL
TFSL
Q4 25
$13.0M
$57.1M
Q3 25
$16.3M
$71.0M
Q2 25
$-30.4M
$25.0M
Q1 25
$-21.2M
$14.3M
Q4 24
$-22.3M
$44.9M
Q3 24
$-8.9M
$85.5M
Q2 24
$-15.4M
$95.9M
Q1 24
$-38.0M
$13.4M
FCF Margin
TARS
TARS
TFSL
TFSL
Q4 25
8.6%
68.2%
Q3 25
13.8%
83.0%
Q2 25
-29.6%
30.5%
Q1 25
-27.1%
18.0%
Q4 24
-33.5%
60.0%
Q3 24
-18.6%
113.8%
Q2 24
-37.8%
127.0%
Q1 24
-137.5%
17.4%
Capex Intensity
TARS
TARS
TFSL
TFSL
Q4 25
4.2%
2.0%
Q3 25
1.6%
13.4%
Q2 25
1.0%
2.1%
Q1 25
0.8%
8.8%
Q4 24
0.1%
0.9%
Q3 24
0.6%
4.1%
Q2 24
2.5%
1.1%
Q1 24
0.6%
1.1%
Cash Conversion
TARS
TARS
TFSL
TFSL
Q4 25
2.64×
Q3 25
3.17×
Q2 25
1.24×
Q1 25
1.01×
Q4 24
2.03×
Q3 24
4.86×
Q2 24
4.85×
Q1 24
0.69×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons